Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist, with top-line data anticipated by mid 2025 and H1 2026, respectively IND filings for ANB033... Read More

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44 th Annual Health Care Conference. Additionally, the company announced an upcoming presentation at the 2024 American Academy... Read More

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6 th Annual Biotechnology Conference. Investor Conference Details Event - Guggenheim’s 6th Annual Biotechnology Conference Format – Fireside chat Date... Read More

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024 Reiterating year-end 2023 cash and investments of $400 to $410 million and cash runway through year-end 2026 SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:... Read More

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small employer category. “This award acknowledges the commitment we’ve made to ensuring Anaptys provides our employees with an exceptional... Read More

Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist Initiating in Q4 2023 a global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab Announced positive top-line Phase 3 clinical trial results of imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) Reiterating cash runway through year-end 2026 and updating expected year-end 2023 cash and investments of... Read More

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November: Investor Conference Details... Read More

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32 nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023. The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data... Read More

Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25. Independent medical experts and... Read More

53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131) Demonstrated favorable safety and tolerability with no SAEs, low incidence and no increase of infections vs. placebo and no cases of DRESS or Guillain-Barre in imsidolimab-treated patients Only one of 30 (3.3%) imsidolimab-treated... Read More

After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of... Read More

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month. Investor Conference Details: Event –... Read More

Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023 Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023 Daniel Faga appointed to the permanent position of president and... Read More

JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Food and Drug Administration approval represents a potential significant driver of JEMPERLI royalties Anticipate top-line data from two GSK Phase 3 studies that include JEMPERLI to read out in 2024: the FIRST study in first-line ovarian cancer (H1 2024) and the COSTAR study in... Read More

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below: Event: Jefferies Healthcare... Read More

Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023 Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 data Initiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be... Read More

Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4 Flare control sustained on monthly subcutaneous doses through Week 16 Imsidolimab was generally safe and well tolerated with low overall ADA incidence Top-line GEMINI-1 Phase 3 trial data expected in Q4 2023 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage... Read More

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company’s Board of Directors. “Rita is a recognized leader in rheumatology with... Read More

Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting 72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically meaningful overall survival trend observed at interim analysis GSK is planning regulatory submissions for the first half of 2023 SAN... Read More

Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023 Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic dermatitis anticipated Q2 2023 Initiating second Phase 2 trial for rosnilimab in an indication to be announced anticipated year-end 2023 Filing IND for ANB033 (anti-CD122 antagonist) anticipated H1 2024 Top-line data from the GEMINI-1... Read More

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m. ET / 11:50 a.m. PT. A live audio webcast of the presentation... Read More

SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and... Read More

Advancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023 Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to treat atopic dermatitis with study initiation in Q2 2023 Advancing rosnilimab into a second Phase 2 trial, in an indication to be announced, with study initiation anticipated by year-end 2023 Blinded interim review of alopecia... Read More

Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of JEMPERLI royalties to AnaptysBio SAN DIEGO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage... Read More